-
Aurora-A Targeting in Translational Oncology
2026-09-01
AURKA overexpression in high-risk retinoblastoma strengthens the case for selective Aurora-A inhibition as a mechanistic research strategy. This article connects the biology of MK-5108 (VX-689) with practical assay design, selectivity interpretation, and translational decision-making.
-
ZK53 and Human ClpP Small-Molecule Design
2026-09-01
The 2025 Future Medicinal Chemistry review organizes recent small-molecule strategies for human mitochondrial ClpP, emphasizing activator design, structure–activity relationships, and anticancer pharmacology. Its discussion of optimized compounds such as ZK53 shows how selective ClpP activation can connect mitochondrial proteostasis disruption with tumor-cell stress, while also highlighting challenges in selectivity, pharmacokinetics, and safety.
-
Cy3-UTP for RNA Trafficking Assay Design
2026-08-31
Cy3-UTP is more than a fluorescent RNA labeling reagent: it can help researchers design better trafficking assays. This guide connects in vitro transcription RNA labeling with interpretation of lipid nanoparticle transport while distinguishing fluorescence, uptake, and functional delivery.
-
Astrocytic GAT-3 Controls Dentate Gyrus Memory
2026-08-31
The reference study identifies astrocytic GAT-3 as an active regulator of entorhinal cortex–dentate gyrus synaptic transmission rather than merely a GABA-clearance mechanism. Its combination of electrophysiology, optogenetics, calcium signaling, and behavioral analysis links GAT-3-dependent astrocyte activation to GluN2B-NMDAR-mediated excitation and contextual fear memory.
-
RapaLink-1: Designing Better mTOR Dormancy Assays
2026-08-30
RapaLink-1 is a third-generation mTOR inhibitor with a bivalent mechanism suited to dissecting durable mTORC1 inhibition, tumor cell suppression, and dormancy-like states. This article translates a recent embryonic dormancy protocol into an assay-design framework while separating established evidence from testable applications.
-
Proteoform-Specific Drug Interactions in Native Membranes
2026-08-29
Lutomski and colleagues developed a native mass-spectrometry workflow that releases membrane proteins and signaling complexes directly from retina rod disc membranes, then sequences their individual proteoforms. The study shows that palmitoylation and other lipid modifications can control membrane association, protein assembly, and off-target ligand interactions, providing a framework for more precise drug-target analysis.
-
Telmisartan in Cardiac Hypertrophy Research
2026-08-28
Use Telmisartan as a defined AT1-receptor perturbation tool in angiotensin II-driven cardiac hypertrophy and hypertension research. Its upstream mechanism complements emerging RIP3/CaMKII studies, enabling cleaner comparisons between receptor blockade, downstream signaling, and cellular remodeling.
-
Elbasvir/Grazoprevir: Evidence for HCV Genotype 1/4 Therapy
2026-08-28
The 2021 review by Wang, Huang, and Yu examines elbasvir/grazoprevir as a dual direct-acting antiviral regimen that combines NS5A and NS3/4A inhibition for hepatitis C. Its main practical contribution is the integration of pharmacology, resistance, efficacy, safety, and special-population evidence, particularly for HCV genotype 1 and 4 infections and patients with renal disease.
-
Dihydroethidium (DHE): From Signal to Mechanism
2026-08-27
Dihydroethidium (DHE) is a cell-permeable hydroethidine probe for investigating superoxide-associated redox changes in live cells. This article explains how to move beyond red fluorescence intensity toward mechanistic interpretation, using recent sonodynamic lung-cancer research to define assay strengths, controls, and limitations.
-
Nelfinavir Mesylate: From HIV to Ferroptosis
2026-08-27
Nelfinavir Mesylate is more than a validated HIV-1 protease inhibitor. Its established antiviral mechanism and emerging ability to perturb the DDI2–NFE2L1–ubiquitin-proteasome axis position it as a valuable translational tool for connecting HIV infection research, proteostasis, and ferroptosis biology.
-
Alternariol: From Toxin Biology to Fibrosis Insight
2026-08-26
Alternariol (AOH) is more than a foodborne mycotoxin reference standard. This thought-leadership guide connects AOH biology, CYP1A metabolism, apoptosis, hepatic stellate cell activation, and translational assay strategy for researchers building stronger fungal toxin studies.
-
Cathepsin B inhibitor CA-074: Practical Guide
2026-08-26
CA-074 (SKU A1926) provides a selective, nanomolar-range tool for separating cathepsin B activity from related cysteine proteases in biochemical and cell-based workflows. It is suitable for controlled studies of cancer metastasis, neurotoxicity reduction via cathepsin B inhibition, and immune response modulation, but its purified-enzyme potency should not be treated as a validated cellular dose or as evidence of broad cathepsin inhibition.
-
Disulfiram in APC-Deficient CRC Assay Design
2026-08-25
Disulfiram can serve as a genotype-informed probe for studying APC-deficient colorectal cancer through ALDH2 inhibition, oxidative stress, and ASK1/JNK signaling. This guide translates the reference findings into practical assay decisions while distinguishing the CRC mechanism from disulfiram’s copper-dependent proteasome activity.
-
Reserpine (N1867): Lab Workflow Guide
2026-08-25
Reserpine (SKU N1867) is a high-purity research reagent for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology research. This guide covers identity checks, DMSO preparation, storage, and quality-control practices; the compound is for research use only and should not be used for diagnostic, therapeutic, or medical applications.
-
Rucaparib: From Splicing State to PARP Assays
2026-08-24
Rucaparib and AG-014699 can do more than quantify PARP dependence: they can help connect DNA damage phenotypes with spliceosome state. This article translates recent SmD2 research into a biologically informed framework for cancer research, radiosensitization, and assay interpretation.